Xeris (XERS) Form 4: Director disposes 107,500 shares at ~$7.32
Rhea-AI Filing Summary
Insider sale of XERS common stock reduced holdings: Director John Johnson sold 107,500 shares of Xeris Biopharma common stock on 08/13/2025 at a weighted average price of $7.3159 per share, leaving him with 833,483 shares beneficially owned. The Form 4 lists the sale as a direct disposition and notes the reported price is a weighted average reflecting multiple trades priced between $7.250 and $7.420. No derivative transactions or additional changes in indirect ownership are reported. The filing was signed by an attorney-in-fact on behalf of the reporting person.
Positive
- None.
Negative
- Director John Johnson executed a direct sale of 107,500 XERS shares, reducing his beneficial ownership to 833,483 shares.
- The sale may represent insider liquidity; the filing does not state a Rule 10b5-1 plan or other rationale for the disposition.
Insights
TL;DR: A director sold 107,500 XERS shares at ~$7.32, reducing direct holdings to 833,483 shares.
The sale is a straightforward, non-derivative disposition reported under Section 16. The transaction was executed in multiple trades at prices between $7.25 and $7.42, producing a weighted average price of $7.3159. Without concurrent disclosure of intentions, planned Rule 10b5-1 activity, or size relative to outstanding shares, this single reported sale is a data point rather than definitive evidence of material change in company outlook. Investors should view this as routine insider liquidity unless corroborated by additional filings or company events.
TL;DR: Director-reported sale is properly disclosed; documentation notes weighted-average pricing across multiple trades.
The Form 4 correctly identifies the reporting person as a director and records a direct disposition. The explanation clarifies the weighted-average price range and offers to provide transaction-level pricing on request, which supports disclosure transparency. There is no indication in the filing of an amendment, a Section 16 exemption, or a Rule 10b5-1 plan election tied to this sale. From a governance compliance standpoint, the filing meets Section 16 reporting requirements as presented.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 107,500 | $7.3159 | $786K |
Footnotes (1)
- F1. The price reported in is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.250 to $7.420, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
AI-generated analysis. How Rhea-AI works. Not financial advice.
